Outcome of Board Meeting held on 12th August 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board approved entering into an agreement with Antelope Valley Cancer Center (AVCC), USA, worth about USD 1 million (~INR 8.65 crores), with potential to rise to USD 1.5 million. B2B will provide AI, Machine Learning, and Agentic Chatbot solutions for AVCC's oncology practice over 5 years. This is flagged as a material related party transaction because AVCC is owned by Dr. Ram Nemani, who is also the company's Promoter and CEO. The Board also recommended continuation of its agreement with GeniusDoc (another promoter-group related party) through 31 December 2030. Other items approved include appointment of Dr. Avinash Yaramati as the new Chairman, a Rs. 20.87 lakh performance bonus for Executive Director Bala Subramanyam Vanapalli, appointment of M/s DSMR & Associates as Secretarial Auditors for 5 years, and appointment of M/s M. Vijaya Kumar & Co. as the new Statutory Auditors following the resignation of M/s Jawahar and Associates. The 31st AGM is scheduled for 29 September 2025 via video conferencing.
The AVCC deal gives B2B a sizeable new revenue stream in the healthcare AI space, but shareholders should note that it is a related party transaction requiring their approval at the AGM. The auditor change and chairman appointment are routine governance matters and unlikely to move the stock materially on their own.